title: Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
abstract: OBJECTIVE
  Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67 proliferation index before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC).
  
  
  METHODS
  Fifty-five patients received neoadjuvant chemotherapy for LABC. The incidence of clinical and pathological responses was assessed with respect to basal clinical stage, absent/low vs. high ER and PgR status, low vs. high proliferation index, grading and Her2 overexpression.
  
  
  RESULTS
  Overall, 30 patients (54%) underwent downstaging of their primary tumor; pathological complete remission was observed in only one patient with Her2 positive breast tumor. Patients with pre-treatment Ki-67 >20%, Her2 overexpression, T2b/T3 vs. T4 clinical stage achieved higher response rate.
  
  
  CONCLUSIONS
  The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors; although the number of patients reported is small, this study confirms that clinical stage at diagnosis, Ki-67 reduction and Her2 overexpression are predictive of tumor response to neoadjuvant regimens.
authors.affiliation: National Institute for Cancer Research, Division of Medical Oncology C, L.go R. Benzi, 10-16132 Genoa, Italy. loredana.miglietta@istge.it
authors.forename: Loredana
authors.initials: L
authors.lastname: Miglietta
authors.forename: Paola
authors.initials: P
authors.lastname: Vanella
authors.forename: Luciano
authors.initials: L
authors.lastname: Canobbio
authors.forename: Maria Angela
authors.initials: MA
authors.lastname: Parodi
authors.forename: Pamela
authors.initials: P
authors.lastname: Guglielmini
authors.forename: Francesco
authors.initials: F
authors.lastname: Boccardo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone